Finance

Lists
Why is NBTX down 3,37%?
Dive Deeper
NBTX:NASDAQ
Nanobiotix SA - ADR
USD 31,50
-3,37%
(-1,10) 1D
29 Sep., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NBTX...
Open
USD 32,47
High
USD 32,47
Low
USD 31,07
Mkt. cap
1,55 mjd
Avg. vol.
153,92 k
Volume
163,48 k
52-wk high
USD 57,00
52-wk low
USD 14,78
EPS
-USD 1,24
Beta
0,75
Shares outstanding
50,62 m
No. of employees
100
Open
USD 32,47
High
USD 32,47
Low
USD 31,07
Mkt. cap
1,55 mjd
Avg. vol.
153,92 k
Volume
163,48 k
52-wk high
USD 57,00
52-wk low
USD 14,78
EPS
-USD 1,24
Beta
0,75
Shares outstanding
50,62 m
No. of employees
100
News stories
From web sources and news partners
Profile
Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts. Wikipedia
About Nanobiotix SA - ADR
CEOLaurent Levy
Employees100
Founded2003
Headquarters-
Sector-
Websitenanobiotix.com
Analyst ratings
Based on 3 analysts giving stock ratings to NBTX in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NBTX in the last 3 months.
Highest
Current USD 31,50
USD 64,00 (+103,17%)
Average
USD 47,00 (+49,21%)
Lowest
USD 30,00 (-4,76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Jeng
Guggenheim
Buy
Maintained
USD 64,00
+103,2%
09/25/2026
David Dai
UBS
Hold
Maintained
USD 30,00
-4,8%
09/25/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
09/25/2026
Michael Schmidt
Guggenheim
Buy
Reiterated
USD 36,00
+14,3%
05/05/2026
Jonathan Chang
Leerink Partners
Buy
Maintained
USD 37,00
+17,5%
04/01/2026
Unknown Analyst
Guggenheim
Buy
Maintained
USD 26,00
-17,5%
02/05/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
13,32 m
13,32 m
2,98 m
2,98 m
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7,26 m
7,26 m
4,29 m
4,29 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,65 m
5,65 m
4,53 m
4,53 m
Operating expense
12,91 m
12,91 m
8,83 m
8,83 m
Total operating expenses
12,91 m
12,91 m
8,83 m
8,83 m
Operating income
407,50 k
407,50 k
-5,85 m
-5,85 m
Other non operating income
500,00
500,00
-8,50 k
-8,50 k
EBT including unusual items
-2,69 m
-2,69 m
-9,29 m
-9,29 m
EBT excluding unusual items
-3,20 m
-3,20 m
-8,57 m
-8,57 m
Income tax expense
3,00 k
3,00 k
-1,50 k
-1,50 k
Effective tax rate
-0,11%
-0,11%
0,02%
0,02%
Other operating expenses
-
-
-
-
Net income
-2,69 m
-2,69 m
-9,29 m
-9,29 m
Net profit margin
-20,21%
-20,21%
-311,97%
-311,97%
Earnings per share
-
-
-
-
Interest and investment income
299,00 k
299,00 k
193,50 k
193,50 k
Interest expense
-2,12 m
-2,12 m
-3,08 m
-3,08 m
Net interest expenses
-1,82 m
-1,82 m
-2,88 m
-2,88 m
Depreciation and amortization charges
-
-
-
-
EBITDA
545,50 k
545,50 k
-5,79 m
-5,79 m
Gain or loss from assets sale
-
-
76,50 k
76,50 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme